‹ ›
MYP_038793
← PREVIOUS NEXT → BACK
Basic Information
A19
Antimicrobial
Antiviral
Antiviral ▸ Anti-HIV ▸ Anti-HIV-1
Antiviral ▸ Antiviral mechanism ▸ Viral entry inhibition
Antiviral ▸ Antiviral mechanism ▸ Viral entry inhibition ▸ Entry inhibitor
Standard
20 amino acids
C110H167N23O27S
Standard
Sequence
LEAIPMSIPPEVKFNKPFAF
Physicochemical Analysis
2275.71 Da
6.14
-0.24
-0.45
-0.0118
0.27
0.30
0.27
59.40
83.00
0.1500
0.00
0.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
771.02
-2.20
23.0
28.0
68.0
161.0
7.0
20.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0023956 VERIFIED: YES
Provenance & Taxonomy
Homo sapiens [Animal]
VIRIP
9606
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antiviral Entry inhibitor
P4-CCR5
>100 μM
IC50
PaperDiscovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. PMID17448989 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/17448989/
RECORD: Rec_0058517 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antimicrobial Antiviral
HIV-1:inhibition of virus infection in P4-CCR5 cells
100 μM
IC50
PaperDiscovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide PMID17448989 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/17448989/
RECORD: Rec_0080247 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
VIRIP-derived peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral Anti-HIV-1 Entry inhibition
HIV-1
100 μM
IC50
Mammalian: 5.5 h; Yeast: 3 min; E. coli: 2 min
PaperDiscovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. | Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F. | Cell. 2007 Apr 20;129(2):263-75. | DOI:10.1016/j.cell.2007.02.042 | PMID:17448989 PMID17448989 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/17448989/
RECORD: Rec_0211908 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antimicrobial Antiviral
PaperDiscovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide PMID17448989 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/17448989/
RECORD: Rec_0372439 VERIFIED: YES
Provenance & Taxonomy
not reported [other]
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antimicrobial Antiviral
PaperHIPdb: a database of experimentally validated HIV inhibiting peptides PMID23359817 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/23359817/